Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Core Insights - Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases [3] Company Overview - Atea specializes in discovering, developing, and commercializing oral antiviral therapies to meet the unmet medical needs of patients with serious viral infections [3] - The company has developed a proprietary nucleos(t)ide prodrug platform aimed at treating single-stranded ribonucleic acid (ssRNA) viruses, which are a significant cause of serious viral diseases [3] - Atea's lead program includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, specifically targeting Hepatitis C Virus (HCV) [3] Upcoming Events - Jean-Pierre Sommadossi, PhD, CEO and Founder of Atea, along with the management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 10:00 a.m. ET in Coral Gables, FL [1] - A live webcast of the presentation will be available on Atea's website, with an archived version accessible for at least 90 days post-event [2]